Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof
AssigneeKarnak Technologies, LLC
InventorsShlomo Magdassi, Liraz Larush, Rafael Ezra
Life of this patent
Estimating the term…
Abstract
The invention discloses particular water-dispersible solid formulation of a cannabinoid or a cannabis extract, wherein they are present in the form of a nanoemulsion, and upon dispersion in water said formulation produces nanoparticles (droplets of a submicron size) with an average size of up to about 500 nm. The present disclosure further relates to methods of making thereof, as well as therapeutic applications in humans for treating disorders and broader application for a range of medical conditions.
Claims21
A water-dispersible powder comprising lipophilic nanospheres having an averaged size between 50 and 900 nm, the nanospheres having an adsorbed layer of at least one solid surfactant and containing a cannabinoid material, wherein the at least one solid surfactant is selected from ammonium glycyrrhizinate, pluronic F-127 and pluronic F68;
- the powder further comprising at least one solid cryoprotectant selected from sucrose, trehalose and mannitol, and optionally at least one solid carbohydrate selected from maltodextrin and carboxymethyl cellulose (CMC);
- wherein the nanospheres' structure and size is substantially maintained upon dissolution in a water containing environment.
(canceled)
5-10. (canceled)
12-33. (canceled)
The powder according to claim 331, wherein the at least one synthetic or natural cannabinoid is selected from tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), a derivative, a precursor and an acid-form thereof.
35-37. (canceled)
42-48. (canceled)
50-55. (canceled)
57-63. (canceled)
65-66. (canceled)
A nanoemulsion comprising lipophilic nanodroplets containing a cannabinoid material and having an averaged size between 50 and 900 nm;
- at least one soluble solid surfactant selected from ammonium glycyrrhizinate, pluronic F-127 and pluronic F68;
- at least one soluble solid cryoprotectant selected from sucrose, trehalose and mannitol, and optionally maltodextrin and carboxymethyl cellulose (CMC).
Dependencies are inferred from the claim text.